Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 19/20 | 0.54 |
| ▸ | MAOA | P21397 | 19/20 | 0.54 |
| ▸ | MAOB | P27338 | 19/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25339542 | 0.80 | KDM1A (0.61) | KDM1AMAOAMAOB | |
| SCHEMBL3682823 | 0.75 | KDM1A (0.40) | KDM1AMAOAMAOB | |
| SCHEMBL12946117 | 0.74 | KDM1A (0.67) | KDM1AMAOAMAOB | |
| SCHEMBL1274251 | 0.74 | KDM1A (0.54) | KDM1AMAOAMAOB | |
| SCHEMBL4331068 | 0.74 | KDM1A (0.67) | KDM1AMAOAMAOB | |
| SCHEMBL1415636 | 0.74 | KDM1A (0.54) | KDM1AMAOAMAOB | |
| Ammonia Solution, Strong SCHEMBL11017865 | 0.72 | KDM1A (0.64) | KDM1AMAOAMAOB | |
| SCHEMBL6151983 | 0.72 | KDM1A (0.50) | KDM1AMAOAMAOB | |
| SCHEMBL16393875 | 0.70 | TSHR (0.39) | KDM1AMAOAMAOB | |
| SCHEMBL8834558 | 0.70 | KDM1A (0.45) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584259-A1 | CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS | Innovo Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024054832-A1 | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-2324002-B1 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | THERACOS SUB LLC (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-2324002-B1 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | THERACOS SUB LLC (US) | 2016-10-05 | — | — | EP | disclosed |
| CN-105237502-A | Processes for the preparation of SGLT2 inhibitors | THERACOS INC | 2016-01-13 | — | — | CN | disclosed |
| US-9006403-B2 | Processes for the preparation of SGLT2 inhibitors | THERACOS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006403-B2 | Processes for the preparation of SGLT2 inhibitors | THERACOS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006403-B2 | Processes for the preparation of SGLT2 inhibitors | THERACOS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| CN-103910702-A | Processes For The Preparation Of Sglt2 Inhibitors | THERACOS INC | 2014-07-09 | — | — | CN | disclosed |
| US-8283454-B2 | Processes for the preparation of SGLT2 inhibitors | THERACOS, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| CN-102177147-A | Process for preparing SGLT2 inhibitors | THERACOS INC | 2011-09-07 | — | — | CN | disclosed |
| EP-2324002-A2 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | Theracos, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100222599-A1 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | THERACOSBIO, LLC | 2010-09-02 | — | — | US | disclosed |
| US-20100222599-A1 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | THERACOSBIO, LLC | 2010-09-02 | — | — | US | disclosed |
| US-20100222599-A1 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | THERACOSBIO, LLC | 2010-09-02 | — | — | US | disclosed |
| WO-2010022313-A2 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | THERACOS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010022313-A2 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | THERACOS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-5563168-A | FUNGICIDES, INSECTICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1996-10-08 | — | — | US | disclosed |
| US-5194662-A | Insecticides, fungicides for plants | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222599-A1 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | SLC5A2, SLC5A1, SLC2A4 | KDM1A 3941/4885MAOA 3420/4885MAOB 3033/4885 |
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | CKS1B, CKS2, MARK1 | KDM1A 69/4885MAOA 3707/4885MAOB 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.